These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

401 related items for PubMed ID: 17051203

  • 1. A century-old debate on protein aggregation and neurodegeneration enters the clinic.
    Lansbury PT, Lashuel HA.
    Nature; 2006 Oct 19; 443(7113):774-9. PubMed ID: 17051203
    [Abstract] [Full Text] [Related]

  • 2. Proteopathy: the next therapeutic frontier?
    Walker LC, LeVine H.
    Curr Opin Investig Drugs; 2002 May 19; 3(5):782-7. PubMed ID: 12090553
    [Abstract] [Full Text] [Related]

  • 3. Strategies for the inhibition of protein aggregation in human diseases.
    Bartolini M, Andrisano V.
    Chembiochem; 2010 May 17; 11(8):1018-35. PubMed ID: 20401887
    [Abstract] [Full Text] [Related]

  • 4. Mechanical stress and formation of protein aggregates in neurodegenerative disorders.
    Hachiya NS, Kozuka Y, Kaneko K.
    Med Hypotheses; 2008 May 17; 70(5):1034-7. PubMed ID: 17910993
    [Abstract] [Full Text] [Related]

  • 5. Modulation of neurodegeneration by molecular chaperones.
    Muchowski PJ, Wacker JL.
    Nat Rev Neurosci; 2005 Jan 17; 6(1):11-22. PubMed ID: 15611723
    [Abstract] [Full Text] [Related]

  • 6. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides.
    Gallardo G, Schlüter OM, Südhof TC.
    Nat Neurosci; 2008 Mar 17; 11(3):301-8. PubMed ID: 18297066
    [Abstract] [Full Text] [Related]

  • 7. Back to the future: the 'old-fashioned' way to new medications for neurodegeneration.
    Lansbury PT.
    Nat Med; 2004 Jul 17; 10 Suppl():S51-7. PubMed ID: 15298008
    [Abstract] [Full Text] [Related]

  • 8. Membrane permeabilization: a common mechanism in protein-misfolding diseases.
    Lashuel HA.
    Sci Aging Knowledge Environ; 2005 Sep 21; 2005(38):pe28. PubMed ID: 16186179
    [Abstract] [Full Text] [Related]

  • 9. [Diseases associated with protein aggregation].
    Bak D, Milewski M.
    Postepy Biochem; 2005 Sep 21; 51(3):297-307. PubMed ID: 16381174
    [Abstract] [Full Text] [Related]

  • 10. How a cell deals with abnormal proteins. Pathogenetic mechanisms in protein aggregation diseases.
    Aigelsreiter A, Janig E, Stumptner C, Fuchsbichler A, Zatloukal K, Denk H.
    Pathobiology; 2007 Sep 21; 74(3):145-58. PubMed ID: 17643060
    [Abstract] [Full Text] [Related]

  • 11. Transgenic animal models of neurodegenerative diseases and their application to treatment development.
    Rockenstein E, Crews L, Masliah E.
    Adv Drug Deliv Rev; 2007 Sep 30; 59(11):1093-102. PubMed ID: 17869376
    [Abstract] [Full Text] [Related]

  • 12. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders.
    Neff F, Wei X, Nölker C, Bacher M, Du Y, Dodel R.
    Autoimmun Rev; 2008 Jun 30; 7(6):501-7. PubMed ID: 18558370
    [Abstract] [Full Text] [Related]

  • 13. Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases.
    Wilhelmus MM, van Dam AM, Drukarch B.
    Eur J Pharmacol; 2008 May 13; 585(2-3):464-72. PubMed ID: 18417122
    [Abstract] [Full Text] [Related]

  • 14. [The role of lithium in neurodegenerative diseases: new registries for old actors].
    Pérez-Martínez DA.
    Neurologia; 2009 Apr 13; 24(3):143-6. PubMed ID: 19418288
    [Abstract] [Full Text] [Related]

  • 15. Mitochondria and neurodegeneration.
    Petrozzi L, Ricci G, Giglioli NJ, Siciliano G, Mancuso M.
    Biosci Rep; 2007 Jun 13; 27(1-3):87-104. PubMed ID: 17486441
    [Abstract] [Full Text] [Related]

  • 16. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
    Barchet TM, Amiji MM.
    Expert Opin Drug Deliv; 2009 Mar 13; 6(3):211-25. PubMed ID: 19290842
    [Abstract] [Full Text] [Related]

  • 17. Unraveling the tangled brain of Alzheimer's.
    Wolfson W.
    Chem Biol; 2008 Feb 13; 15(2):89-90. PubMed ID: 18291309
    [No Abstract] [Full Text] [Related]

  • 18. A network dysfunction perspective on neurodegenerative diseases.
    Palop JJ, Chin J, Mucke L.
    Nature; 2006 Oct 19; 443(7113):768-73. PubMed ID: 17051202
    [Abstract] [Full Text] [Related]

  • 19. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease.
    Olcese JM, Cao C, Mori T, Mamcarz MB, Maxwell A, Runfeldt MJ, Wang L, Zhang C, Lin X, Zhang G, Arendash GW.
    J Pineal Res; 2009 Aug 19; 47(1):82-96. PubMed ID: 19538338
    [Abstract] [Full Text] [Related]

  • 20. Fitting neurological protein aggregation kinetic data via a 2-step, minimal/"Ockham's razor" model: the Finke-Watzky mechanism of nucleation followed by autocatalytic surface growth.
    Morris AM, Watzky MA, Agar JN, Finke RG.
    Biochemistry; 2008 Feb 26; 47(8):2413-27. PubMed ID: 18247636
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.